Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate

Rivaroxaban: A New Oral Factor Xa Inhibitor

(2010) Elisabeth Perzborn et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials

(2010) Yong Bing Cao et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials

(2010) R.J. Friedman et al.   THROMBOSIS RESEARCH

Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents

(2009) M. A. CROWTHER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS

Biochemical comparison of seven commercially available prothrombin complex concentrates

(2008) U. Kalina et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature

(2007) Cindy A. Leissinger et al.   AMERICAN JOURNAL OF HEMATOLOGY